Skip to main content
[Preprint]. 2024 Mar 27:2024.03.24.584499. [Version 1] doi: 10.1101/2024.03.24.584499

Figure 2. In vitro characterization of mLumiOpto technology.

Figure 2.

(a) IVIS imaging showed that ViviRen elicited dose-dependent bioluminescent responses in mLumiOpto plasmid-transfected cancer cells. (b) Confocal imaging showed that ViviRen induced mLumOpto-mediated mitochondrial depolarization in a dose-dependent manner, as measured by MitoView 633, a mitochondrial membrane potential-dependent fluorescent dye (red). (c) ViviRen caused dose-dependent cell death in mLumiOpto-transfected TNBC (MDA-MB-231) cells but had no obvious cytotoxic effect in mock-transfected cells. (d) mLumiOpto caused substantial cytotoxicity in multiple cancer cell lines, including GBM cells (U251 and U87) and TNBC cells (BT-20 and MDA-MB-468). n=4–6/group.